The Skin Health Institute Board is delighted to announce the appointment of David Malone as the new CEO of Skin Health Institute.
David’s passion and commitment to improving health outcomes sustainably and engaging stakeholders were key factors in his appointment to the role.
David comes to us from the Department of Health where he has held many roles since 2018, with the most recent being Director, Medical Research and International Health. David led the teams responsible for COVID-19 pathology operations within the department, as well as the development of Victoria’s Public Health and Wellbeing Plan for 2019-2023.
David has a Bachelor of Science, a Bachelor of Applied Science, and a Master of Business Administration. He has previously held Chief Executive Officer positions at the Australian Primary Health Care Nurses Association, the Western Australian Health Promotion Foundation (Healthway) and the Australian Physiotherapy Association. David has also been an Advisor to the World Health Organisation.
Quote from David:
“I’m very excited to be joining an organisation that has such a strong legacy of delivering world-class dermatological care to thousands of patients every year for over three decades. SHI really is a unique organisation, with its mission of research, education, and high-quality clinical services for skin conditions and skin cancers. I’m looking forward to working with the Board, staff, and the stakeholders of SHI, to grow the business and drive its ongoing success.”
David will commence in his new role on Monday 3rd October.
It is with great sadness that we farewell Caroline Mulcahy, who will leave the Skin Health Institute after three years, which included bravely leading us through the pandemic. Caroline has been terrific; we will miss her and wish her well in her new role as Chief Executive at Sexual Health Victoria.
ANNOUNCEMENT OF NEW CEO
Psoriasis, a chronic inflammatory skin condition, affects millions of individuals worldwide, including a significant number of Australians. This August, during Psoriasis Awareness Month, we aim to shed light on this prevalent condition, raise awareness, and emphasise the importance of empathy and support for those living with psoriasis.
In Australia, psoriasis is estimated to impact approximately 2-3% of the population, making it a relatively common dermatological concern. Despite its prevalence, psoriasis remains widely misunderstood, leading to misconceptions and stigmatisation among patients.
At the Skin Health Institute, we have committed our support to Psoriasis Awareness Month with a mission to create empathy and awareness for people with psoriasis and promote a better understanding of this condition. We recognise that beyond medical treatment, patients need compassionate support and understanding from their communities. Through various initiatives, we strive to foster an environment of compassion and knowledge, allowing patients to feel heard and supported as they learn to manage their condition.
Our dedication to enhancing dermatological care extends to providing the latest treatment options. Our Advanced Targeted Therapies Clinic offers cutting-edge therapies that specifically address psoriasis, tailored to each patient’s unique needs. Our expert dermatologists work closely with patients to develop personalised treatment plans, empowering them to manage their condition effectively and improve their quality of life.
Education is key to unlocking progress in dermatology, so through our suite of educational resources, we seek to help health professionals to stay at the forefront of their clinical practice. Our Masterclasses, GP Workshops, Advanced Therapeutics Education Portal, and Spot Diagnosis podcast episodes provide valuable insights and updates on psoriasis management and treatment options.
As part of our commitment to advancing psoriasis research, we are actively conducting clinical trials focused on nail and body psoriasis. These trials play a crucial role in uncovering innovative treatments and improving outcomes for people with psoriasis. By participating in our clinical trials, individuals not only contribute to medical advancements but also have the opportunity to access potential breakthrough therapies.
During Psoriasis Awareness Month and beyond, we stay dedicated in the pursuit of improving patient outcomes, expanding healthcare professional knowledge and advancing treatment options.
